Kenta Biotech Reports 100% survival Panobacumab life-threatening hospital-acquired pneumonia
admin | Apr 16, 2010 | 0 comments
Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired Pneumonia
BERNE, Switzerland—-Kenta Biotech has presented positive Phase IIa results of its lead drug candidate, panobacumab , with all patients completing the treatment for hospital-acquired pneumonia and ventilator-acquired pneumonia caused by P. aeruginosa achieving an effective clearance of pneumonia as well as a 100% survival rate.
Filed Under: Health and Ill
